 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates ADCs for patients with hematologic malignancies and solid tumors, today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET. Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel 